Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Juvenile Idiopathic Arthritis.

Kenan Barut1, Amra Adrovic1, Sezgin Şahin1

  • 1Department of Pediatric Rheumatology, İstanbul University Cerrahpaşa Medical School, İstanbul, Turkey.

Balkan Medical Journal
|April 19, 2017
PubMed
Summary

Juvenile idiopathic arthritis (JIA) is a complex childhood rheumatic disease with various subtypes. Recent advancements in therapeutics have significantly improved JIA treatment outcomes, leading to sustained joint damage reduction and clinical improvement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Nailfold Videocapillaroscopy in Pediatric Rheumatology: Established Roles, Emerging Applications, and Future Perspectives.

Balkan medical journal·2026
Same author

Systemic JIA-Associated Lung Disease: A Multicenter Analysis of Clinical Features, Treatment Challenges, and Outcomes.

Pediatric pulmonology·2026
Same author

What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort.

Journal of scleroderma and related disorders·2026
Same author

Predictors of severe coronary involvement in children with Kawasaki disease: a single-centre cohort study.

Cardiology in the young·2026
Same author

Idiopathic recurrent pericarditis in children: a tertiary care cohort highlighting the emergence and effectiveness of interleukin-1 blockade.

European journal of pediatrics·2026
Same author

Ongoing Challenges in Pediatric Care in the Balkan Region: An Example of Northern Macedonia.

Turkish archives of pediatrics·2026

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Genetics

Background:

  • Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, presenting with diverse clinical manifestations and subtypes.
  • Subtypes include systemic JIA (fever, rash), oligoarticular JIA (females, uveitis), polyarticular JIA (seropositive/seronegative), enthesitis-related arthritis (spondyloarthropathies), and psoriatic arthritis.
  • Complications range from growth issues and osteoporosis to life-threatening macrophage activation syndrome.

Purpose of the Study:

  • To review the classification, clinical features, complications, and evolving treatment strategies for juvenile idiopathic arthritis.
  • To highlight the impact of novel therapeutics on long-term outcomes in pediatric patients with JIA.

Main Methods:

  • Review of current literature on juvenile idiopathic arthritis classification and treatment.
Keywords:
Juvenile idiopathic arthritisbiologic therapy in childhoodpediatric rheumatology chronic arthritis in childhood.

Related Experiment Videos

  • Analysis of the efficacy and safety of conventional disease-modifying anti-rheumatic drugs (DMARDs) and advanced biologic agents.
  • Discussion of the multidisciplinary team approach in managing JIA.

    • Main Results:

    • New therapeutics, including anti-tumour necrosis factor, anti-interleukin-1, anti-interleukin-6, and T-cell regulatory agents, have demonstrated safety and efficacy.
    • These advanced treatments have led to sustained reduction in joint damage and complete clinical improvement in many pediatric patients.
    • The advent of these therapies marks a significant improvement in JIA treatment and long-term prognosis.

    Conclusions:

    • Modern therapeutic strategies have transformed the management of JIA, offering improved long-term outcomes.
    • Timely and aggressive treatment, utilizing a combination of conventional DMARDs, corticosteroids, and biologics, is crucial for disease control.
    • A multidisciplinary approach is essential for optimizing joint function, growth, and preventing long-term damage in children with JIA.